These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4024044)

  • 1. Water-soluble urokinase derivatives with increased affinity to the fibrin clot.
    Maksimenko AV; Torchilin VP
    Thromb Res; 1985 May; 38(3):289-95. PubMed ID: 4024044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Water-soluble modified derivatives of urokinase: fibrinolytic activity and other properties].
    Maksimenko AV; Torchilin VP
    Vopr Med Khim; 1985; 31(4):12-20. PubMed ID: 4049780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Water-soluble urokinase derivatives of combined action.
    Maksimenko AV; Torchilin VP
    Thromb Res; 1985 May; 38(3):277-88. PubMed ID: 4024043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic urokinase: targeting of urokinase to fibrin clot.
    Yoshimoto T; Ohwada K; Takahashi K; Matsushima A; Saito Y; Inada Y
    Biochem Biophys Res Commun; 1988 Apr; 152(2):739-43. PubMed ID: 3365251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
    Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
    Ferres H
    Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin.
    Ruppert C; Markart P; Schmidt R; Grimminger F; Seeger W; Lehr CM; Günther A
    Thromb Haemost; 2003 Jan; 89(1):53-64. PubMed ID: 12540954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clot-selective coronary thrombolysis with pro-urokinase.
    Loscalzo J; Wharton TP; Kirshenbaum JM; Levine HJ; Flaherty JT; Topol EJ; Ramaswamy K; Kosowsky BD; Salem DN; Ganz P
    Circulation; 1989 Apr; 79(4):776-82. PubMed ID: 2494004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R; Fears R; Smith RA
    Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current developments in thrombolytic therapy using novel plasminogen activators.
    Seifried E; Tanswell P
    Arzneimittelforschung; 1989 Nov; 39(11):1474-82. PubMed ID: 2695093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolytic action of urokinase preparation covalently bound to modified thrombin].
    Maksimenko AV; Tishvhenko EG; Petrov AD; Orekhova NM; Ragimov SE
    Biull Eksp Biol Med; 1988 Sep; 106(9):322-4. PubMed ID: 3167185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition.
    Bernik MB
    J Clin Invest; 1973 Apr; 52(4):823-34. PubMed ID: 4266421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
    Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
    J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.